These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20644626)

  • 21. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.
    Gordon CE; Uhlig K; Lau J; Schmid CH; Levey AS; Wong JB
    Am J Kidney Dis; 2008 Feb; 51(2):263-77. PubMed ID: 18215704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.
    Thong VD; Poovorawan K; Tangkijvanich P; Wasitthankasem R; Vongpunsawad S; Poovorawan Y
    Intervirology; 2015; 58(6):373-81. PubMed ID: 27010195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First Week HCV RNA Level Under the Pegylated Interferon and Ribavirin Treatment Predicts Sustained Virological Response.
    Bayram M; Koksal AR; Alkim H; Boga S; Ergun M; Ozdogan O; Altinkaya E; Alkim C
    Am J Ther; 2016; 23(6):e1612-e1618. PubMed ID: 25933139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
    Oze T; Hiramatsu N; Yakushijin T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Nagase T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Imai Y; Kato M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Gastroenterol; 2011 Jul; 46(7):944-52. PubMed ID: 21552988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
    Wang X; Liu F; Wei F; Ren H; Hu H
    PLoS One; 2014; 9(6):e100128. PubMed ID: 24963667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
    Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
    Oze T; Hiramatsu N; Yakushijin T; Mochizuki K; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Hosui A; Miyagi T; Ishida H; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Gastroenterol; 2011 Aug; 46(8):1031-7. PubMed ID: 21538029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
    Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J;
    BMC Infect Dis; 2017 Jun; 17(1):420. PubMed ID: 28610605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
    Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.
    Allen AM; Kim WR; Larson J; Loftus EV
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1655-60.e1. PubMed ID: 23891915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    BMC Infect Dis; 2012 Nov; 12():324. PubMed ID: 23181537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.